

Annex B: Summary of Baselines and Targets for Gavi 5.0 Mission and Strategy Indicators¹

Indicator	Baseline (2019)	2025 Target	Rationale
Mission Indicators			
M.1 Under-five mortality rate (SDG 3.2.1)	55/1,000	TBD	TBD - Target not yet defined due to uncertainty around how UN-IGME estimates of child mortality will reflect COVID-related health impacts. It is anticipated that baseline and targets for this indicator will be submitted to the PPC and Board in the Fall/Winter of 2021.
M.2 Future deaths averted	n/a	7-8m	Target made as part of the commitments in the Gavi 2021-2025 Investment Opportunity
M.3 Future DALYs averted	n/a	320-380m	Target closely aligned with future deaths averted targets, calculated using the same methodology from the Vaccine Impact Modelling Consortium (VIMC).
M.4 Reduction in number of zero-dose children	9.7m	-25%	Target based on the Alliance's ambition to reduce zero dose by 25% by 2025—half the level of ambition established by IA2030 of reducing number of zero-dose children globally and for each country by 50% by 2030 as compared to 2019.
M.5 Unique children immunised	n/a	300m	Target made as part of the commitments in the Gavi 2021-2025 Investment Opportunity,
M.6 Economic benefits unlocked	n/a	US\$80-100b	Target made as part of the commitments in the Gavi 2021-2025 Investment Opportunity.

¹ Baselines are based on current immunisation coverage estimates and available data. For many indicators, baseline estimates may be revised as new data become available (i.e., absolute values may change but the level of ambition will be retained).

Indicator	Baseline (2019)	2025 Target	Rationale
STRATEGY GOAL 1: INTRODUCE AND SCALE UP VACCINES			
S1.1 Breadth of protection	-50% ²	+16pp ³	Summary coverage indicator for all Gavi-supported vaccines. Ambition based on the forecasted Gavi57 coverage across individual vaccines would imply a target of +18pp (breath of protection of 68% in 2025 based on current estimates for the 2019 baseline). The pentavalent coverage forecast is based on the ambition to reduce zero-dose by 25%, while forecasts of new vaccines are based on the Gavi operational forecast v18 (OP18), with the exception of MCV2 where OP18 was modified for countries introducing in 2018 and later to be consistent with the S.1.3 target of reaching 90% of the MCV1 coverage within 3 years of introduction and the IA2030 target of having drop-out rates no greater than 5% by 2030. The exception was made for MCV2 as it is administered at a separate visit from the other vaccines (e.g., pentavalent and PCV), so forecasting scale-up and coverage requires more specific assumptions. The final target of +16pp is derived by applying a 10% reduction to the aggregate value assuming the ambition across each and every component forecast may not be fully realised.
S1.2 SDG 3.b.1 (DTP3, MCV2, PCV3, HPV coverage)	DTP3: 81% MCV2: 58% PCV3: 53% HPV2: 8%	DTP3: +4pp MCV2: +13pp PCV3: +23pp HPV2: +17pp	DTP3: 2025 target established based on ambition to reduce zero-dose children by 25% and linear progress towards IA2030 target for DTP1-DTP3 drop-out rate of no more than 5% by 2030. DTP3 coverage would be 85% in 2025 based on current estimates for the 2019 baseline. MCV2: 2025 target established based on a combination of OP18 and forecasts consistent with S.1.3 and IA2030 targets (see above). Coverage would be 71% in 2025 based on current estimates for the 2019 baseline. PCV3: 2025 target established based on OP18. Coverage would be 76% in 2025 based on current estimates for the 2019 baseline and assuming an additional year to complete subnational scale-up in India HPV2: 2025 target established based on OP18, which assumes lower country demand to account for uncertainties associated with COVID disruptions and country preferences for new HPV products. Coverage would be 25% in 2025 based on current estimates for the

² Per the 5.0 definition of breadth of protection, which includes HPV and IPV2

³ pp = percentage points

			2019 baseline. If country demand were to match that of supply, coverage could be as high as 30% in 2025
S1.3 Rate of scale up of new vaccines	PCV3: 94% Rotac: 92% MCV2: 92% YF: 86%	90% for each antigen	2025 target is based on the ambition that all mature introductions will have scaled up to within 10% of the reference vaccine coverage within 2 or 3 years. This is consistent with the target used in Gavi 4.0. The target is based on a two-year period for PCV3 and Rotac and a three-year period for MCV2 and yellow fever vaccine.
S1.4 Vaccine introductions	n/a	TBD	TBD - Targets not yet defined although it is anticipated it will fall somewhere within the range of 70-90 new routine introductions, excluding IVP2 and COVID vaccines. It is anticipated that baseline and targets for this indicator will be submitted to the PPC and Board in the Fall/Winter of 2021.
S1.5 Country prioritisation of vaccines	TBD	TBD	TBD - Targets not yet defined. It is anticipated that baseline and targets for this indicator will be submitted to the PPC and Board in the Fall/Winter of 2021.
S1.6 Preventive campaign reach (measles)	TBD	TBD	TBD - Targets not yet defined. It is anticipated that baseline and targets for this indicator will be submitted to the PPC and Board in the Fall/Winter of 2021.
S1.7 Timely outbreak detection and response	TBD	TBD	TBD - Target not yet defined. Benchmarks are close to being finalized through discussions within IA2030 M&E, and it is anticipated that baseline and targets for this indicator will be submitted to the PPC and Board in the Fall/Winter of 2021.

Indicator	Baseline (2019)	2025 Target	Rationale
STRATEGY GOAL 2: STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION			
S2.1 Geographic equity DTP3 coverage	67%	+7pp	Midpoint of forecasted range of +5pp to +9pp based on translating 25% reduction in zero-dose at national level down to district level in country reported administrative data.
S2.2 DTP drop-out	7%	-1pp	Target set assuming linear progress towards the IA2030 ambition of drop-out being no more than 5% by 2030.
S2.3 MCV1 coverage	80%	+4pp	2025 target is +4pp from baseline. Same relative change as DTP3. Rationale for DTP3 targets described in discussion of targets for indicator SDG 3.b.1 above. MCV1 coverage would be 84% in 2025 based on current estimates for the 2019 baseline.
S2.4 Number of immunisation sessions	n/a	n/a	No quantitative target will be set for 2025. Indicator results will be monitored for directionality of change and trends.
S2.5 Stock availability	n/a	n/a	No quantitative target will be set for 2025. Indicator results will be monitored for directionality of change and trends.
S2.6 EPI management capacity	n/a	n/a	No quantitative target will be set for 2025. Indicator results will be monitored for directionality of change and trends.
S2.7 Percentage of countries implementing tailored plans to overcome demand barriers	n/a	n/a	No quantitative target will be set for 2025. Indicator results will be monitored for directionality of change and trends.
S2.8 Percentage of countries addressing gender-related barriers with Gavi support	n/a	n/a	No quantitative target will be set for 2025. Indicator results will be monitored for directionality of change and trends.

Indicator	Baseline (2019)	2025 Target	Rationale
STRATEGY GOAL 3: IMPROVE SUSTAINABILITY OF IMMUNISATION PROGRAMMES			
S3.1 Co-financing fulfilment	100%	100%	All countries applying for and/or receiving Gavi vaccine support are required to co-finance a portion of the cost.
S3.2 Preventing backsliding in routine immunisation coverage in Gavi-transitioned countries	TBD	TBD	TBD – Measurement of backsliding has not yet been defined. Definition of indicator, and associated targets, pending finalisation and Board approval of the Gavi's strategy for engaging Middle Income Countries (MICs).

Indicator	Baseline	2025 Target	Rationale
STRATEGY GOAL 4: ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS			
S4.1 Number of markets exhibiting acceptable supply dynamics	TBD	TBD	TBD - target to best established following approval of the revised Market Shaping Strategy by the Gavi Board.
S4.2 Number of innovative products within the pipeline with commercial-scale manufacturers	TBD	TBD	TBD - target to best established following approval of the revised Market Shaping Strategy by the Gavi Board.
S4.3 Number of vaccine and immunisation-related products with improved characteristics	TBD	TBD	TBD - target to best established following approval of the revised Market Shaping Strategy by the Gavi Board.